The FDA has approved obecabtagene autoleucel (Aucatzyl) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

LOUISVILLE, Ky. -- A CD70-targeted CAR T-cell therapy for advanced kidney cancer continued to show durable activity in ...

所有患者在输注 CART-123 前都接受了氟达拉滨（fludarabine）和环磷酰胺（cyclophosphamide）淋巴细胞清楚的标准调理治疗。 在评估反应的六名患者中 ...

A new research paper titled "ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells" has been published in Oncotarget.

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

Q3 2024 Earnings Call Transcript November 7, 2024 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

These presentations highlight strong evidence of anti-tumor activity of ALLO-316 following standard FC (fludarabine (30 mg/m2) and cyclophosphamide (500 mg/m2)) lymphodepletion in patients with CD70 ...

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

Current recommendations suggest treating elderly CLL patients with good physical status and low burden of comorbidities with chemoimmunotherapy, consisting of non-fludarabine-based regimens.

Nkarta is working on engineered NK cell therapies for autoimmune diseases and cancer. Click here to find out why I maintain a ...

Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes #469 oral presentation Session: 626.